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In this issue of the Journal of Thoracic Oncology, Stephans et al. from the ClevelandClinic report their review of pulmonary function testing (PFT) before and after
stereotactic body radiation therapy (SBRT) for stage I lung cancer.1 Though retrospective,
this contribution is meaningful. The “believers” know that SBRT offers a substantial
improvement in local control with relatively little toxicity compared with conventionally
fractionated radiation therapy for these medically inoperable patients. The “skeptics” are
fearful that the delivery of such high doses of radiation therapy may not be safe in the long
run for this frail patient population. Stephans et al. show data that are consistent with two
other datasets, that forced expiratory volume in 1 second FEV1% and diffusing capacity
of the lung for carbon monoxide remain relatively unchanged following SBRT.2,3
Local control rates of 85 to 90% are now expected with SBRT for T1-2N0 lung
cancers, provided that biologic equivalent doses of 100 Gy are employed.4 Multiple
radiation oncology centers from around the world using multiple delivery technologies
have demonstrated this level of effectiveness.5–8 These individual centers have also
reported acute and late toxicities, which have been low (5%). Until recently, there has
been a paucity of data showing the effect of SBRT on PFT. Prospective trials may lend
validity to these results. Phase I/II prospective studies have recently been completed by the
Radiation Therapy Oncology Group (RTOG 0236)9 and Japanese Cooperative Oncology
Group (JCOG 0403). Results from these trials are pending. A phase III randomized trial
comparing SBRT to surgery is just underway for operable patients in The Netherlands
(ROSEL trial). Further prospective studies evaluating SBRT for lung cancer are either
ongoing or are being planned. Completion of these trials is important to verify these
results in a multicenter setting and to promote the option of SBRT to pulmonologists,
medical oncologists, and surgeons who also manage these patients.
Looking more closely at the current manuscript, a few questions are raised that need
further evaluation from others. Are there patients with PFT results that are too low to be
treated with SBRT? Are patients with central tumors more apt to experience decline in
PFTs (i.e., due to centrally located fibrosis or atelectasis)? Does a higher conformality
index really result in greater PFT decline? These are important questions that often arise
but remain unknown. Stephans et al. report a patient with an FEV1% as low as 15% who
is locally controlled and without complications. Larger multicenter databases may provide
a larger set of patients on which to base a PFT threshold. Of the 10 patients treated for
centrally located tumors, no PFT difference has yet been encountered, though they were
treated with a gentler dosing schedule. The RTOG just initiated a separate SBRT trial for
patients with centrally located tumors (RTOG 0813). The intent of the RTOG trial is to
determine the maximum tolerated dose to a bronchus using five fractions, and to determine
the effectiveness of that dose. Also in the current dataset, a higher conformality index
resulted in greater PFT loss, implying that there may be a threshold for the number of
beams used above which the low-dose volume becomes too high. What should the 5 Gy
isodose volume be limited to? As the number of beams increases, so does the 5 Gy isodose
volume. This has implications for SBRT planning and delivery.
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In summary, Stephans et al. provide additional data that
pulmonary function within the medically inoperable stage I
lung cancer population does not significantly decline follow-
ing SBRT. Multicenter prospective trials that collected PFT
data have recently completed or are ongoing. Hopefully,
prospective data will support these findings and provide
additional insights with respect to appropriate patient selec-
tion and optimal delivery of SBRT. In the meantime, both
local control and toxicity data for SBRT remain encouraging.
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